MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Teva Pharmaceutical Industries Ltd.

Open

SectorGezondheidszorg

14.73 1.1

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

14.46

Max

14.76

Belangrijke statistieken

By Trading Economics

Inkomsten

162M

-275M

Verkoop

-103M

4.2B

EPS

0.71

Winstmarge

-6.503

Werknemers

33,892

EBITDA

51M

261M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+62.09% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

16B

Vorige openingsprijs

13.63

Vorige sluitingsprijs

14.73

Technische score

By Trading Central

Vertrouwen

Very Strong Bullish Evidence

Teva Pharmaceutical Industries Ltd. Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

17 dec 2024, 19:39 UTC

Belangrijke Marktbewegers

Correction to Teva Articles

17 dec 2024, 16:24 UTC

Belangrijke Marktbewegers

Teva Soars, Sanofi Gains on Strong Trial Results for IBD Treatment

17 dec 2024, 16:14 UTC

Acquisities, Fusies, Overnames

These Stocks Are Moving the Most Today: Nvidia, Tesla, Broadcom, Pfizer, EVgo, Teva, SolarEdge, Affirm, and More -- Barrons.com

17 dec 2024, 13:51 UTC

Acquisities, Fusies, Overnames

These Stocks Are Moving the Most Today: Nvidia, Tesla, Broadcom, Pfizer, EVgo, Teva, SolarEdge, Red Cat, and More -- Barrons.com

23 nov 2024, 12:00 UTC

Top Nieuws

Emerging-Markets Stocks Have Rarely Been So Hated. It's Time To Buy -- WSJ

22 aug 2024, 05:30 UTC

Top Nieuws

Generic Weight-Loss Drugs Won't Come for Years -- Barrons.com

7 mei 2024, 20:30 UTC

Top Nieuws

Teva Earnings Are Soon. What Could Keep the Stock Gains Going. -- Barrons.com

Peer Vergelijking

Prijswijziging

Teva Pharmaceutical Industries Ltd. Prognose

Koersdoel

By TipRanks

62.09% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 23.86 USD  62.09%

Hoogste 30 USD

Laagste 20 USD

Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor Teva Pharmaceutical Industries Ltd. - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

8 ratings

7

Buy

1

Hold

0

Sell

Technische score

By Trading Central

13.44 / N/ASteun & Weerstand

Korte Termijn

Very Strong Bullish Evidence

Gemiddeld Termijn

Weak Bearish Evidence

Lange Termijn

Weak Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Teva Pharmaceutical Industries Ltd.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.